FR2997853A1 - Reducing or delaying the thinning of skin and the sagging of skin and stimulating cellular metabolism of keratinocytes, comprises applying effective quantity of an extract of Myrothamnus flabellifolia to skin - Google Patents

Abstract

Delaying or reducing the thinning of skin and sagging of skin, comprises applying an effective quantity of an extract of Myrothamnus flabellifolia to the skin. Independent claims are included for: (1) a composition including an extract of Myrothamnus flabellifolia, rhamnose and a cosmetically acceptable medium; and (2) preparing the cosmetic composition including, mixing rhamnose with the extract of Myrothamnus flabellifolia and the cosmetically acceptable medium.

Description

The present invention relates to a cosmetic treatment method intended to reduce and / or delay the thinning of the skin, and / or the loosening of the skin and to reduce the risk of skin aging. and / or to improve the density and / or the barrier function of the skin by applying an effective amount of an extract of Myrothamnus flabellifolia alone or as a mixture with at least one hexose to the skin, such a composition and its use as a cosmetic ingredient. Women and men tend to want to look young for as long as possible and therefore seek to fade the marks of aging skin. Human skin consists of three compartments namely: a superficial compartment, the epidermis, the dermis, and a deep compartment, the hypodermis. The epidermis is a keratinized stratified squamous epithelium. It consists mainly (90 (3/0) of keratinocytes, but also other cells (melanocytes and Langerhans cells), and is based on a basement membrane that separates it from the dermis.The epidermis is composed of several layers of cells , the deepest of which is the basal layer of undifferentiated cells, which over time will differentiate and migrate to the surface of the epidermis, thus forming the different cellular layers up to the stratum corneum on the surface of the epidermis. The organization and especially the cohesion of these different cell layers is made possible by a set of intercellular junctions.These junctions are generally formed of three structures: transmembrane proteins, molecules of intracellular attachment forming a structure called " cytoplasmic plaque "and cytoskeletal fibers inserted on said cytoplasmic plate. no tight junction between two keratinocytes creating a fusion zone of the plasma membranes between two cells. The tight junctions consist of occcludins and claudines as transmembrane molecules, zonulin-1 (ZO-1) and zonulin-2 (ZO-2) forming the cytoplasmic plate and finally spectrin and actin under of cytoskeletal fibers. These tight junctions create a seal between two keratinocytes forming a barrier between the interior (the dermis) and outer (the superficial layers of the epidermis) as well as a polarization of the plasma membrane according to whether it is above or below of this area of tight junctions.

In addition, there are adherent junctions that are the anchor junctions. They can be in macular or zonular form. In the zonular form, the transmembrane molecules are cadherins, the cytoplasmic plaque is composed of catenins and plakoglobin and the cytoskeleton molecules are actin molecules. These junctions form a belt located just below the tight junction and thus help maintain the homeostasis of the epithelial tissue. The actin filaments attached to them give them a certain contractility. These junctions intervene between several keratinocytes but also between keratinocytes and melanocytes.

In macular form, these anchorage junctions are called desmosomes. The desmosomes are furthermore composed of transmembrane proteins of the cadherin family (desmocollin and desmoglein), the cytoplasmic plate consists of plakoglobin and desmoplakin and the cytoskeleton elements are intermediate filaments. These junctions play a vital role in the structure and maintenance of the epidermis. These networks contribute to the architectural cohesion of the epidermis and allow the transmission and the damping of the mechanical forces exerted on the keratinocytes. It should be noted that these different junctions are localized variably according to the layer of the epidermis concerned. Thus, the tight junctions are found in the basal layers whereas the adherent junctions are found mainly in the intermediate layers. These latter junctions are nevertheless present even in the most superficial layers namely the stratum corneum. The stratum corneum consists of corneocytes which are dead cells which are eliminated by desquamation and an extracellular matrix formed of lipid lamellae.

These lipid lamellae synthesized by keratinocytes form the extracellular cement of the stratum corneum and have a role of protecting the epidermis. The process of desquamation of the stratum corneum is made possible by the finely regulated disruption of intercellular junction systems such as desmosomes. This elimination of the superficial layers of the epidermis is compensated by the migration of cells from the basal layer to the surface of the epidermis. It is the balance between these two processes that allows the perpetual renewal of skin cells. The epidermis rests on a deeper tissue: the dermis. This tissue forms a real foundation for the epidermis and is responsible for its nutrition. The dermis is a connective tissue. Its architecture results from the arrangement and the interactions between the constituents of the extracellular matrix and the fibroblasts which ensure their synthesis and their degradation. Other cellular constituents are involved in the immune system (macrophages and mast cells) or are related to the presence of blood vessels (endothelial, muscle and nerve cells). The dermis constitutes the main mass of the skin. The dermis is divided into two layers, papillary and reticular. The dermis consists of collagen and elastic fibers as well as glycosaminoglycans and proteoglycans. These different structures form a complex network that plays a key role in the biomechanical properties of the skin. The hypodermis is the deepest and thickest compartment of the skin. It is invaginated in the dermis and is attached to the underlying dermis by collagen and elastin fibers. It consists essentially of a type of cells specialized in the accumulation and storage of fat, adipocytes. The hypodermis acts as an energy reserve and participates in the mechanical properties of the skin, as well as in the thermoregulation of the body, since the fat is a thermal insulator. The mechanical properties of the skin in vivo depend on many physiopathological parameters and are influenced by various parameters as mentioned above. These parameters include age, sex, anatomical sites. The dermo-epidermal junction (JDE) ensures cohesion between the epidermis and the dermis. In optical microscopy, this junction appears as a wavy line alternating the projections of the epidermis in the dermis, called "epidermal ridges", and those of the dermis in the epidermis, called "dermal papillae", which together form the papillary dermis. JDE is a complex region about 100 nm thick that includes the basal keratinocyte basal pole, the epidermal basement membrane, and the sub-basal area of the superficial dermis. JDE has, at the level of keratinocytes and melanocytes, anchoring complexes of the epidermis on the dermis. In the basal keratinocytes, hemidesmosomes and basal melanocytes of the focal contacts are described. Hemidesmosomes and focal-contacts are intracellularly composed of cytoplasmic plaques associated with actin cytoskeleton for focal-contacts and tonofilaments for hemi-desmosms. The transmembrane proteins are integrins. Hemidesmosomes mediate cell signaling through integrins. They play a very important role in large cellular functions such as adhesion, migration and proliferation of keratinocytes by transmitting inter-cellular signals (Hynes et al., 1992). In addition, integrins interact with receptors of many growth factors and thus regulate the proliferation of keratinocytes. Thus, the expression of integrins would be altered during certain skin cancers and induced during cell migration in the context of physiological phenomena (scarring, renewal of the epidermis). Integrins interact on the intracellular side with the cytoplasmic plaque proteins talin and vinculin for focal contacts and plectin for hemidesmosomes. On the extracellular side, integrins interact with elements of the extracellular matrix (ECM) that are fibronectin or laminin. These elements of the extracellular matrix are also called anchoring filaments. They cross the epidermal basement membrane to penetrate into the dermis where they constitute with the collagen fibers I, III and V and the microfibrils the sub basal network. The JDE provides fundamental functions: it has a role of mechanical support for the adhesion of the epidermis to the dermis and a selective barrier role allowing the control of molecular and cellular exchanges between the two compartments. It is, through the glycoproteins that make it up - in particular laminins - support for the adhesion and migration of keratinocytes during the restoration of epidermal integrity, a fundamental step in cutaneous healing. During aging, there is an irregularity of the stratum corneum which is characterized by an increase in its thickness in some areas, a thinning in other places and a reduction of the extracellular cement. This causes an alteration of the desquamation process and disorganization of the stratum corneum. With age, there is also a reduction in the thickness of the epidermis, the density of the skin and a decrease of about 50% in the renewal of the cells of the epidermis. This mechanism is at the origin of the more intense exposure of epidermal cells to ultraviolet rays, thus contributing to a greater incidence of cutaneous cancers. But also this leads to a weakening of the epidermis and slowing the healing of wounds and any lesion of the skin.

This weak cell renewal is linked to two cumulative phenomena. The first is the decrease in keratinocyte metabolism with age, which is characterized by a decrease in the proliferation capacity of keratinocytes. The second is due to the slower migration of basal keratinocytes to the surface of the epidermis and the accumulation of senescent keratinocytes.

Aging also results in a reduction of the entire junction system responsible for cell-cell and cell-MEC cohesion as well as a reduction in tight junctions, especially at the level of the basal cells. A direct consequence of this reduction of tight junctions is the reduction of the effectiveness of the barrier function of the skin.

In addition, there is described a decrease in expression of integrins, thus a reduction of hemidesmosomes which is furthermore associated with the decrease of anchor fibril synthesis by dermal fibroblasts having reduced activity. Thus, the remaining hemidesmosomes are no longer sufficient to ensure the junction between the dermis and the epidermis. This decrease in the cohesion between the dermis and the epidermis, linked to a decrease in adhesion of the keratinocytes to the extracellular matrix, contributes to a reduction of the firmness of the skin, to a loosening of the skin and to the appearance of wrinkles. The reduction of expression of integrins has indeed consequences on the cellular mechanisms in which they intervene. In particular, keratinocyte proliferation may be mentioned, but also the migration of these cells into the epidermis, allowing the renewal of the layers of the epidermis or cicatrization. The reduction of the entire epidermal junction system (between the keratinocytes, between keratinocytes and melanocytes) and at the level of the JDE (keratinocyte or melanocyte and MEC) contributes to the reduction of the cellular cohesion and therefore to the reduction the mechanical resistance of the skin, its loosening, its loss of firmness and consequently, the appearance of wrinkles. A means of combating aging described in the prior art is the forced elimination of the stratum corneum which accelerates cell renewal. This means can be somewhat traumatic for the skin and must be done under strict conditions to be really effective.

It is therefore interesting to find active agents capable of stimulating cell metabolism for good quality skin, stimulating cell-cell and cell-MEC connections to reinforce the skin barrier, cell cohesion and the mechanical resistance of the skin for a long time. skin firmer and less wrinkled. The expression wrinkles result from mechanisms different from those generating wrinkles due to aging. Precisely, they are produced under the effect of the stress exerted on the skin by the skin muscles which allow mimicry. Depending on the shape of the face, the frequency of mimicry and possible tics, they can appear from childhood. Expression lines are characterized by the presence of grooves around the orifices of the nose (nasolabial folds), the mouth (parabulary wrinkles and so-called bitterness wrinkles) and the eyes (wrinkles of the paw 'oie), around which lie the skin muscles, as well as between the eyebrows (wrinkles of the glabella or the lion) and on the forehead. Until now, the only means commonly used to act on expression lines are, on the one hand, botulinum toxin which is in particular injected into the wrinkles of the glabella and, on the other hand, degradable implants based on collagen, hyaluronic acid or polylactic acid.

We therefore understand the importance of having compositions whose effects aim to regenerate skin tissues via an increase in the proliferation of keratinocytes by stimulating the metabolism of keratinocytes. It is known from the literature the use of agents, such as retinol, which promote the proliferation of keratinocytes and make it possible to stimulate the renewal of the epidermis, maintain and / or increase the thickness of the epidermis. This is called a direct biological effect. However, retinol has a number of disadvantages for cosmetic use. Indeed, it has a low stability with respect to oxidation and generates undesirable side effects for consumers, such as in particular the irritation of the skin. There is therefore a need to find other compounds having a direct biological effect that are easily accessible and have an acceptable efficacy for optimal use in cosmetics. In this regard, the Applicant has surprisingly and unexpectedly discovered that an extract of Myrothamnus flabellifolia is capable of stimulating the metabolism of keratinocytes, of increasing the expression of molecules involved in the connections between epidermal cells as well as the adhesion of epidermal cells basal to JDE. It is therefore expected that such an extract can counteract the signs of skin aging and in particular improve the mechanical strength of the skin or its biomechanical properties, improve the barrier function of the skin, control the relaxation of the skin. skin and / or improve the density of the skin by stimulating the migration of keratinocytes and their proliferation. The Applicant has also demonstrated a significant increase in these effects when the extract of Myrothamnus flabellifolia is combined with rhamnose. The invention therefore relates to a cosmetic treatment method for decreasing and / or delaying thinning of the skin, loosening of the skin and / or improving the mechanical strength of the skin and / or the density of the skin and / or the barrier function of the skin, characterized in that an effective amount Myrothamnus flabellifolia is applied alone or in combination with rhamnose on the skin. The invention further relates to a composition comprising an extract of Myrothamnus flabellifolia and at least one hexose such as rhamnose. The invention finally relates to the use of a cosmetic composition comprising an extract of Myrothamnus flabellifolia alone or in combination with rhamnose as an agent for reducing and / or delaying the thinning of the skin, and / or the relaxation of the skin. skin and / or improve the mechanical strength of the skin and / or the density of the skin and / or the barrier function of the skin.

Therapeutic treatments of the human or animal body are excluded from the scope of the invention. In the context of the present application, the "loosening of the skin" refers to the normal relaxation (related to aging) and the relaxation which is a consequence of a pathology, and is for example in the form of skin withered, soft skin, or skin thinned. Looseness is one of the signs of skin aging and may be related to environmental stress (eg pollution, photoaging, UV radiation, especially UV-A and / or UV-B), variation in the organization the density of the hypodermis (changes in body mass, pregnancy, obesity, cellulitis), drug treatment (eg corticosteroids) or even disorganization of extracellular matrix constituents (eg, stretch marks, scars, pressure ulcers ). Skin laxity may also be the consequence of a disorder of gene expression (Cutis laxa, Ehler Danlos, Marfan Syndrome, Werner's Syndrome).

In the context of the present application, "thinning of the skin" refers to the reduction in the average thickness of the layers of the skin and in particular the layers of the epidermis. Such thinning is evaluated by measuring cutaneous thickness from cutaneous biopsy by immunohistochemical techniques. The "density of the skin" can be evaluated by the densicore which is an apparatus which locally subjects the skin to a mechanical stress generating wrinkles whose number and amplitude are directly related to the skin density. In the context of this application, "mechanical strength of the skin" refers to the ability of the skin to maintain its structural integrity under the exercise of a deformation force. This force can be in particular, pressure, torsion or stretching. Resistance to mechanical stresses such as rubbing, abrasion, shaving, frequent hand washing can be evaluated in the laboratory by the use of devices such as the cutometer. The cutometer is a suction device consisting of a cylinder 1 to 3 mm in diameter that is applied to the skin. The aspiration of the skin via a pump connected to the cylinder induces a vertical displacement of the skin which makes it possible to evaluate the mechanical properties of the skin. By "biomechanical properties of the skin" is meant here the properties of extensibility, tonicity, firmness, suppleness and / or elasticity of the skin. By "effective amount" is meant in the sense of the present invention an amount sufficient to achieve the expected effect.

The method according to the invention is in particular intended to stimulate the cellular metabolism of keratinocytes and / or the migration and / or proliferation of keratinocytes and / or to reinforce the cohesion between the epidermal cells and / or between the epidermal cells and the extracellular matrix and more particularly to strengthen the adhesion of basal epidermal cells to the JDE. According to the present invention, the stimulation of cellular metabolism of keratinocytes and thus the cellular renewal of the epidermis makes it possible to reduce the dull appearance of the stratum corneum of the epidermis and thus to improve the radiance of the complexion, to diminish and / or prevent the pigment spots, improve and / or reduce the micro-relief of the skin, to smooth the skin and / or to improve the mechanical properties of the skin and / or promote the repair of the skin.

The evaluation of keratinocyte metabolism stimulation is determined by the measurement of various parameters such as glucose consumption, energy production (ATP) or respiration (measurement of the NAD / NADH marker ratio of the mitochondrial respiratory chain). cell) keratinocytes before and after the application of the composition according to the invention.

The reinforcement of the cohesion between the epidermal cells and / or between the epidermal cells and the extracellular matrix is made possible by the implementation of the method according to the invention since the latter makes it possible to stimulate the formation of desmosomes, hemidesmosomes, contacts and / or tight junctions of the epidermis preferentially by stimulating the synthesis of integrin and / or zonulin by keratinocytes. Thus, the induction of intercellular connections and extracellular cell-matrix makes it possible to strengthen the dermal-epidermal junction, to increase the firmness of the skin and thus to reduce and / or prevent the occurrence of wrinkles and / or fine lines, to improve and / or or to reduce the micro-relief of the skin, to smooth the skin and / or to improve the mechanical properties of the skin (in particular the mechanical strength and / or tone of the skin) and / or the barrier function of the skin. The term "skin barrier" refers to the barrier function of the epidermis and JDE against the potential entrances or exits of water, ions or molecules and against the penetration of chemicals or chemicals. infectious agents. This function is fulfilled (i) by the extracellular cement of the stratum corneum (inter-corneocytic cement) which constitutes a hydrophobic barrier, (ii) by the tight junctions of the basal layer of the epidermis forming a zone of fusion between two keratinocytes thus ensuring a selective barrier against micro or macromolecule ions and finally (iii) by the JDE which forms a filtration zone by its structure of macromolecules organized in a network. The improvement of this barrier function is made possible by the stimulation of the metabolism of the keratinocytes responsible for the synthesis of the extracellular cement of the cornea, by the induction of the expression of zonulins by the keratinocytes responsible for the tight junctions and the integrins involved. in hemi-desmosomes allowing anchoring of the basal layer of keratinocytes in the dermis and the architectural stability of the JDE.

Biological markers to distinguish different junctions and thus assess their density are described. Thus, the markers of tight junctions are zonulin-1 (ZO-1), zonulin-2 (ZO-2), occuldine or claudine. At the epidermal level and depending on their localization, these proteins are involved in barrier function, cell polarity, cell differentiation and proliferation as well as intracellular vesicular trafficking (Kirschner N, Ann NY Acad Sci 2012 Jun; 1257: 158 -66). Intercellular junctions such as adherent junctions and desmosomes are responsible for the architecture and cohesion of epidermal cells. Thus, the markers of the adherent junctions are cadherin (cadherin-E and cadherin-P), catenin (alpha-catenin or beta-catenin) or plakoglobin (Lai-Cheong JE, J. Invest Dermatol 2007 Dec; 127 (12 ): 2713-25). The desmosome markers are desmocollin (DSC1, DSC2 or DSC3), desmoglein (DSG1, DSG2 or DSG3), desmoplakin (DP1, DP2) or plakoglobin (PP1 and PP2). Functional abnormalities of these proteins have been implicated not only in autoimmune pathologies but also in the maintenance of epidermal homeostasis (McMillan JR, J Dermatol, 2001 Jun, 28 (6): 291-8). A particular class of desmosome is represented by the corneodesmoses involved in the maturation of the stratum comeum (Jonca N, Eur J Dermatol, 2011 May, 21 Suppl 2: 35-42). The markers of cohesion between the epidermis and the dermis are the proteins of hemidesmosomes such as integrins (such as, for example, integrin alpha 4) and plectin. The α4 integrin plays an important role in this adhesion. With age its expression decreases which contributes to a softer, more wrinkled skin. Markers of focal contacts such as integrins, talin or vinculin can be used. At the epidermal level, these integrins participate not only in the adhesion process but also in keratinocyte proliferation and differentiation, intracellular signaling pathways, re-epithelialization during skin healing, as well as maintenance of the skin. hair growth and maintenance of stem cells (Margadant C, FASEB J. 2010 Nov; 24 (11): 4133-52). At the dermal level, integrins allow contact between cells and matrix components thus ensuring mechanical properties attributed to the dermis (Silver FH, Skin Res Technol, 2003 Feb; 9 (1): 3-23).

The present invention also relates to the use of an extract of Myrothamnus flabellifolia as an agent for decreasing and / or delaying the thinning of the skin and / or the relaxation of the skin and / or improving the mechanical resistance of the skin and / or or the density of the skin and / or the barrier function of the skin, said extract of Myrothamnus flabellifolia being contained in a cosmetic composition. Preferably, said composition comprises at least one hexose. According to a preferred embodiment, the use according to the present invention is intended to improve the radiance of the complexion, to reduce and / or prevent the characteristics of wrinkles and / or fine lines, to reduce and / or prevent pigment spots, to to improve and / or reduce the micro-relief of the skin, to smooth the skin and / or to improve the mechanical properties of the skin (in particular elasticity and / or tone of the skin) and / or to promote the repair of the skin. Mvrothamnus flabellifolia extract Myrothamnus flabellifolia is a small shrub belonging to the family of resurrection plants. It grows on shallow granitic soils subject to drought during the dry months of winter. Resurrection plants have the particularity of drying out at the same time as their environment and remain for months in a state of anhydrobiosis. In times of drought, plants dry up almost without loss of their leaves that dry out and fold back on themselves. In the dry state, live shoots contain only 7 to 11% water (by weight). After rain, the plant rehydrates very quickly even after a long period of drought. In some species, the dry leaves may turn green and the metabolism of the plant (perspiration, photosynthesis) restart measurably a few hours after rehydration.

The pharmaceutical or cosmetic use of an extract of Myrothamnus flabellifolia has been described for the protection of the skin vis-à-vis external aggressions and especially ultraviolet, free radicals or heat in the US2007 patent application / 0134193. As described in the patent application U52007 / 0134193, the extract of Myrothamnus flabellifolia is likely to be obtained by extraction in an aqueous medium, alcoholic or hydro-alcoholic, from a portion or the whole of the plant. Such extraction processes include maceration, remacerization, digestion, shaking maceration, vortex extraction, ultrasonic extraction, countercurrent extraction, percolation, repercolation, extraction. under reduced atmosphere or evacuation (extraction under reduced pressure), diacolation, solid / liquid extraction at reflux, or extraction using separators, centrifuges and decanters. Fresh or dried plants, preferably the leaves, can be used indifferently. Prior to extraction, the plant can be milled. Suitable solvents for the extraction process are distilled water or not, organic solvents, more particularly low molecular weight alcohols such as aliphatic alcohols having from 1 to 6 carbon atoms (for example, methanol or methanol). ethanol), ketones (eg acetone), halogenated hydrocarbons (for example chloroform or methylene chloride), lower esters or polyols (for example, glycerol or glycols). The extraction process is usually carried out at 20 to 100 ° C. In order to avoid oxidation of the active ingredients of the extract, the extraction can be done under an inert gas atmosphere. After extraction, the crude extracts obtained may optionally be subjected to other conventional steps, such as, for example, purification, concentration and / or bleaching. The solvent used in the extraction can be removed by drying, in particular by spraying or lyophilization.

Typically, an extract of Myrothamnus flabellifolia can be obtained according to Examples 1 and 2 of US2007 / 0134193. Such an extract can be used in its dry (powdery) form or solubilized in a solvent such as water. Such a solubilized form preferably contains 0.3 to 2% by weight of dry matter (DM) of extract, relative to the total weight of the solution, preferably 0.4 to 1.5%, even more preferably 0.5 to 1`) / ode MS. Such an extract is sold under the trade reference PA REVIVISCENCE® LS 9562 by the company BASF and / or Laboratoires Serobiologiques. The extracts can also be used as raw materials for the production of pure active ingredients.

Advantageously, the extract of Myrothamnus flabellifolia is present in the composition according to the present invention at a content of 10-6 to 10%, preferably of 5.10-6 to 8%, preferably of 7.10-6 to 7%, and preferably at a level of 8.10-6 to 5%; 10-6 to 2%; 2.10-6 at 1%; 4.10-6 to 0.8%; 5.10-6 to 0.7%; 7.10-6 to 0.5%; 0.0001 to 0.2%; 0.00022 to 0.1%; 0.0003 to 0.09%; 0.0005 to 0.07%; 0.0007 to 0.05%, 0.0009 to 0.01% by weight of extract (MS), relative to the total weight of the composition, in particular 11.10-4% by weight Hexose According to the present invention, we mean by "hexose" a monosaccharide having 6 carbon atoms. The hexose according to the invention is rhamnose.

The hexose according to the invention is of natural or synthetic origin, it can be linear or cyclic. Preferably, the hexose according to the invention is ungrafted. By the term "non-grafted" is meant an unsubstituted or free hexose or a hexose that has not had subsequent reaction of the side chains with another chemical compound. Preferably, an ungrafted hexose is a hexose which is not covalently bound to a polypeptide, an aliphatic chain, a protein, a polysaccharide or a lipid or to a phosphate, amine, acid, sulphate or acetyl group or to a radical alkyl or aryl. Rhamnose (or 6 deoxy mannose) is the deoxygenation product of mannose in 06. Mannose is a hexose epimer in 02 glucose. The monosaccharides according to the invention are in the form of D- or L-rhamnose or their mixture, each form may itself be the alpha and / or beta anomer. The preferred forms according to the invention are D-rhamnose (CAS No. 634-74-2) or L-rhamnose (CAS No. 3615-41-6 (anhydrous L); CAS No. 10030-85-0 (L (+ ) - monohydrate)). The most preferred form is L-rhamnose. D-mannose is present in plants, particularly certain fruits including cranberries (cranberries), or hardwood (beech, birch). Rhamnose is found in nature in L form. L-rhamnose is marketed, for example, by Danisco Sweeteners as well as Symrise. The rhamnose is in powder form (such as a crystalline powder) or in solution.

Advantageously, at least one hexose chosen from rhamnose is added to the composition according to the invention, in addition to the Myrothamnus flabellifolia extract, so as to obtain a composition having a final content of 0.001 to 30% by weight of hexose. , relative to the total weight of the composition. Preferably, said at least one hexose according to the invention is present in the composition according to the present invention in a content of 0.001 to 30%, preferably from 0.002 to 20%, and most preferably said at least one hexose is added in the composition according to the invention in addition to the Myrothamnus flabellifolia extract so as to obtain a composition having a content of 0.003 to 15%; by weight of hexose, in particular from 0.004% to 12%; 0.005 to 10%; 0.008 to 9%; 0.01 to 7%; 0.015 to 5%; 0.0017 to 3%; 0.02 to 2.5%; 0.025 to 2%; 0.03 to 1%, 0.05 to 0.5%, especially 0.08% relative to the total weight of the composition. When D-rhamnose and L-rhamnose are added to the composition, the hexose content and in particular the rhamnose indicated corresponds to the sum of their respective contents.

Galenic For the implementation of the process or the use according to the invention, the extract of Myrothamnus flabellifolia is formulated in a cosmetic composition further comprising at least rhamnose. Said composition further comprises a cosmetically or physiologically acceptable medium. Said composition being obtained by a preparation process comprising at least one step of mixing rhamnose (and in particular, a rhamnose solution or a pulverulent rhamnose composition), an extract of Myrothamnus flabellifolia and a medium cosmetically acceptable. Preferably, the rhamnose is added to the extract of Myrothamnus flabellifolia in said composition. In the context of the present invention, the weight ratio between the said at least one hexose and the extract of Myrothamnus flabellifolia (hexose / Myrothamnus flabellifolia extract) in the composition is greater than 1, it is preferably from 1 to 107 and all in particular from 2 to 5 × 10 6, and in particular from 10 to 10 6; 20 to 5.105; 25 to 105; 30 to 5.104; 35 to 104; 38 to 5000; 40 to 3500; 42 to 3000; 45 to 2500; 48 to 2000; 50 to 1500; 53 to 1000; 55 to 800; 58 to 600; 60 to 500; 62 to 300.65 to 100 or 68 to 90. For carrying out the process or the use according to the invention, the composition according to the invention is more particularly intended to be applied to the areas of the body, face or forehead, in particular marked by wrinkles, and / or or on people with wrinkles. The combination of at least one extract of Myrothamnus flabellifolia and at least one hexose is formulated for administration preferably topically, that is to say containing a cosmetically acceptable medium, or a medium compatible with the skin , nails, mucous membranes, tissues, scalp and / or hair.

The combination can be formulated in the form of a cosmetic composition, that is to say intended to be applied to a healthy skin to improve the aesthetics and especially comfort. Healthy skin is defined as the absence of pathologies such as infections, inflammation, erythema, or wounds such as a burn or a cut. However, in this definition, healthy skin does not mean skin in perfect condition. The cosmetic composition is thus formulated to be applied to the skin and comprises an extract of Myrothamnus flabellifolia and at least one hexose, said composition making it possible to reduce and / or delay the signs of aging of the skin, and in particular to reduce and / or delay the aging of the skin. thinning of the skin, loosening of the skin and / or improving the mechanical strength of the skin and / or the density of the skin and / or the barrier function of the skin.

According to a preferred embodiment of the invention, the composition has a pH close to that of the skin, between 4 and 7. The composition according to the invention is advantageously intended for topical application (composition for topical use).

When applied topically, the cosmetic composition may be applied to the face, neck, scalp, mucous membranes and nails or any other skin area of the body including the hands and feet. By "acceptable physiological medium" or "cosmetically acceptable medium" is meant a medium that is compatible with the skin or the materials and / or the keratinous fibers of human beings, such as, for example, without limitation, the skin, the mucous membranes. , nails, scalp and / or hair. Such a medium does not generate tingling, tightness or redness unacceptable to the user and is without risk of toxicity, incompatibility, instability, allergic response and others. This physiologically or cosmetically acceptable medium comprises water, optionally mixed or not with one or more organic solvents such as C 1 -C 8 alcohols, in particular ethanol, isopropanol, tert-butanol and n-butanol. polyols such as glycerine, propylene glycol, butylene glycol and polyol ethers. The compositions according to the invention are especially in the form of aqueous, hydroalcoholic or oily solutions, dispersions of the lotion or serum type, anhydrous or oily gels, emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion. a fatty phase in an aqueous phase (O / W) or conversely (W / O), multiple emulsions (triple: W / H / E or H / E / H), suspensions or consistency emulsions soft, semi-solid or solid type cream, gel, especially aqueous, microemulsions, or lipid vesicles of ionic and / or nonionic type (liposomes, niosomes, oleosomes), or thin films, or micro -capsules, micro-particles. It is also possible to use a composition according to the invention in the form of a water and oil biphase. The amounts of the various constituents of the cosmetic compositions used according to the invention are those conventionally used in the fields under consideration.

These compositions are prepared according to the usual methods. In addition, the compositions used according to the invention may be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. They may optionally be applied to the skin in the form of an aerosol. They may also be in solid form, for example in the form of a stick.

In particular, the cosmetic composition may be in the form of a transparent gel. In particular, this transparent gel is characterized by the fact that it is obtained by combining the active agents with a homopolymer of a monomer containing a sulfonic group. More particularly, said gel contains from 0 to 1% of oil.

The polymers comprising at least one monomer containing a sulfonic group, used in this type of transparent gel, are advantageously water-soluble or water-dispersible or swellable in water. The polymers used for this type of transparent gel are homopolymers that can be obtained from at least one ethylenically unsaturated monomer and with a sulfonic group, which can be in free form or partially or completely neutralized. Preferably, the polymers used for this type of transparent gel may be partially or completely neutralized with a mineral base (sodium hydroxide, potassium hydroxide, ammonia) or an organic base such as mono-, di- or triethanolamine, an aminomethylpropanediol, N-methylglucamine, basic amino acids such as arginine and lysine, and mixtures of these compounds. They are usually neutralized. The term "neutralized" in the present invention means polymers that are totally or substantially completely neutralized, that is to say neutralized to at least 90%. These polymers generally have a number average molecular weight ranging from 1000 to 20,000,000 g / mol, preferably from 20,000 to 5,000,000 and even more preferably from 100,000 to 1,500,000 g / mol. These polymers according to the invention may be crosslinked or non-crosslinked. The monomers containing the sulfonic group of the polymer used in these transparent gels are chosen in particular from vinylsulfon acid, styrene sulphonic acid, (meth) acrylamido (C 1 -C 22) alkylsulphonic acids and N- (C 1 -C 22) acids. alkyl- (meth) acrylamido (C1-C22) alkylsulfonic acids such as undecyl-acrylamidomethanesulfonic acid, as well as their partially or completely neutralized forms, and mixtures thereof. According to a preferred embodiment of the invention, the monomers containing a sulfonic group are chosen from (meth) acrylamido (C1-C22) alkylsulphonic acids, such as, for example, acrylamido-methanesulfonic acid and acrylamidoethane acid. sulphonic acid, acrylamido-propanesulfonic acid, 2-acrylamido-2-methylpropanesulfonic acid, 2-methacrylamido-2-methylpropanesulphonic acid, 2-acrylamido-n-butanesulfate 2-acrylamido-2,4,4-trimethylpentanesulfonic acid, 2-methacrylamido-dodecylsulphonic acid, 2-acrylamido-2,6-dimethyl-3-heptanesulfonic acid, and as their partially or totally neutralized forms, and their mixtures. More particularly, 2-acrylamido-2-methylpropanesulfonic acid (AMPS) and its partially or completely neutralized forms are used.

As other polymers suitable for this type of gel, mention may be made in particular of the crosslinked and neutralized homopolymer of 2-acrylamido-2-methylpropanesulphonic acid, marketed by the company Clariant under the trademark "Hostacerin® AMPS" (name CTFA: ammonium polyacryldimethyltauramide, INCI name: Ammonium polyacryloyl dimethyl taurate.

The homopolymer of monomer containing a sulfonic group may be present in a transparent gel in an active material content ranging, for example, from 0.05 to 5% by weight, preferably from 0.1 to 5% by weight. by weight, preferably ranging from 0.05 to 2% by weight, for example from 0.1 to 0.4%, especially from 0.25% by weight relative to the total weight of the composition.

When the composition used according to the invention, whatever its nature, comprises an oily phase, it preferably contains at least one oil. It may also contain other fatty substances. As oils that may be used in the cosmetic composition, mention may be made for example of: hydrocarbon-based oils of animal origin, such as perhydrosqualene; hydrocarbon-based oils of vegetable origin, such as liquid triglycerides of fatty acids containing from 4 to 10 carbon atoms, for instance triglycerides of heptanoic or octanoic acids or, for example, sunflower, corn or soybean oils, squash, grape seed, sesame, hazelnut, apricot, macadamia, arara, sunflower, castor oil, avocado, triglycerides of caprylic / capric acids such as those sold by Stearineries Dubois or those sold under the names Miglyol 810, 812 and 818 by the company Dynamit Nobel, jojoba oil, shea butter oil; esters and synthetic ethers, especially of fatty acids, such as the oils of formulas R1000R2 and R10R2 in which R1 represents the residue of a fatty acid containing from 8 to 29 carbon atoms, and R2 represents a hydrocarbon-based chain, branched or unbranched, containing from 3 to 30 carbon atoms, such as, for example, purcellin oil, isononyl isononanoate, isopropyl myristate, ethyl-2-hexyl palmitate, octyl stearate, -2-dodecyl, octy1-2-dodecyl erucate, isostearyl isostearate; hydroxyl esters such as isostearyl lactate, octyl hydroxystearate, octyldodecyl hydroxystearate, diisostearyl malate, triisocetyl citrate, heptanoates, octanoates, decanoates of fatty alcohols; polyol esters, such as propylene glycol dioctanoate, neopentyl glycol diheptanoate and diethylene glycol diisononanoate; and pentaerythritol esters such as pentaerythrityl tetraisostearate; linear or branched hydrocarbons of mineral or synthetic origin, such as paraffin oils, volatile or not, and their derivatives, petroleum jelly, polydecenes, hydrogenated polyisobutene such as parleam oil; fatty alcohols having 8 to 26 carbon atoms, such as cetyl alcohol, stearyl alcohol and their mixture (cetylstearyl alcohol), octyldodecanol, 2-butyloctanol, 2-hexyldecanol, 2-undecylpentadecanol, oleic alcohol or linoleic alcohol; partially fluorinated hydrocarbon oils and / or silicone oils such as those described in document JP-A-2-295912; silicone oils such as volatile or non-volatile polymethylsiloxanes (PDMS) with a linear or cyclic silicone chain, which are liquid or pasty at room temperature, in particular cyclopolydimethylsiloxanes (cyclomethicones) such as cyclohexasiloxane; polydimethylsiloxanes comprising alkyl, alkoxy or phenyl groups, during or at the end of the silicone chain, groups having from 2 to 24 carbon atoms; phenyl silicones such as phenyltrimethicones, phenyldimethicones, phenyltrimethylsiloxydiphenylsiloxanes, diphenyldimethicones, diphenylmethyldiphenyltrisiloxanes, 2-phenylethyltrimethylsiloxysilicates, and polymethylphenylsiloxanes; - their mixtures. The term "hydrocarbon-based oil" in the list of oils mentioned above, any oil predominantly comprising carbon and hydrogen atoms, and optionally ester, ether, fluoro, carboxylic acid and / or alcohol groups. The other fatty substances that may be present in the oily phase are, for example, fatty acids containing from 8 to 30 carbon atoms, such as stearic acid, lauric acid, palmitic acid and oleic acid; waxes such as lanolin, beeswax, carnauba or candelilla wax, paraffin waxes, lignite waxes or microcrystalline waxes, ceresin or ozokerite, synthetic waxes such as polyethylene waxes, waxes Fischer-Tropsch; silicone resins such as trifluoromethyl-C1-4-alkyldimethicone and trifluoropropyldimethicone; and silicone elastomers such as the products sold under the names "KSG" by the company Shin-Etsu, under the names "Trefil", "BY29" or "EPSX" by the company Dow Corning or under the names "Gransil" by the company Grant Industries. These fatty substances may be chosen in a varied manner by those skilled in the art in order to prepare a composition having the desired properties, for example of consistency or texture. According to a particular embodiment, the cosmetic composition is a water-in-oil (W / O) or oil-in-water (O / W) emulsion. The proportion of the oily phase of the emulsion can range from 5 to 80% by weight and preferably from 5 to 50% by weight relative to the total weight of the composition.

The emulsions generally contain at least one emulsifier chosen from amphoteric, anionic, cationic or nonionic emulsifiers, used alone or as a mixture, and optionally a co-emulsifier. The emulsifiers are suitably selected according to the emulsion to be obtained (W / O or O / W). The emulsifier and the coemulsifier are generally present in the composition, in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight. Of the composition For the W / O emulsions, examples of emulsifiers that may be mentioned include dimethicone copolyols such as the mixture of cyclomethicone and dimethicone copolyol, sold under the name "DC 5225 C" by the company Dow Corning, and the alkyls dimethicone copolyols such as Laurylmethicone copolyol sold under the name Dow Corning 5200 Formulation Aid by the company Dow Corning and Cetyl dimethicone copolyol sold under the name Abil0 EM 90 by the company Goldschmidt, It is also possible to use as surfactant emulsions. E / H, a crosslinked solid elastomeric organopolysiloxane comprising at least one oxyalkylenated group, such as those obtained according to the procedure of Examples 3, 4 and 8 of US-A-5,412,0 04 and examples of US-A-5,811,487, including the product of Example 3 (synthetic example) of US-A-5,412,004 and such as that sold under the reference KSG 21 by Shin Etsu. Other types of KSG marketed by Shin Etsu can also be used, such as KSG-16.

For O / W emulsions, mention may be made, for example, as emulsifiers, of nonionic emulsifiers such as oxyalkylenated (more particularly polyoxyethylenated) fatty acid esters of glycerol; oxyalkylenated fatty acid and sorbitan esters; oxyalkylenated fatty acid esters (oxyethylenated and / or oxypropylenated); oxyalkylenated fatty alcohol ethers (oxyethylenated and / or oxypropylenated); sugar esters such as sucrose stearate; and mixtures thereof such as the mixture of glyceryl stearate and PEG-40 stearate.

In known manner, the cosmetic composition may also contain adjuvants customary in the cosmetic or dermatological field, such as hydrophilic or lipophilic gelling agents, preservatives, solvents, perfumes, fillers, UV filters, bactericides, odor, dyestuffs, plant extracts, salts, antioxidants, basic agents, acids, nonionic, anionic, cationic surfactants. The amounts of these various adjuvants are those conventionally used in the field under consideration, and for example from 0.01 to 20% of the total weight of the composition, these adjuvants, depending on their nature, may be introduced into the fatty phase, In the aqueous phase and / or in the lipid vesicles, fillers which may be used in the composition of the invention include, for example, in addition to pigments, silica powder, colloidal amorphous silica, talc; polyamide particles and in particular those sold under the name ORGASOL by the company Atochem, polyethylene powders, micro-spheres based on acrylic copolymers, such as those made of ethylene glycol dimethacrylate / lauryl methacrylate copolymer sold by Dow Corning under the name of Polytrap, expanded powders such as hollow microspheres and in particular, the microspheres marketed under the name EXPANCEL by the company Kemanord Plast or under the name MICROPEARL F 80 ED by the company Matsumoto; silicone resin microbeads such as those sold under the name Tospearl by the company Toshiba Silicone; and their mixtures. These fillers may be present in amounts ranging from 0 to 20% by weight and preferably from 1 to 10% by weight relative to the total weight of the composition.

As hydrophilic or lipophilic gelling agents, mention may be made in particular of carbopol, luvigel, Hostacerin® AMPS, Simulgel, Sepigel-type acrylamide gelling agents such as Sepigel 305® from Seppic, xanthan gums, guar gums and cellulose gums. alginates and mixtures thereof. We can also mention hectorites. Antioxidant agents that may be mentioned include polyphenols, tannic acid, epigallocathechine derivatives thereof and natural extracts containing them, anthocyanins, rosemary extracts, olive leaf extracts, green tea, resveratrol and its derivatives, Pycnogenol, ergothineine, N acetylcysteine, biotin, chelants, idebenone, plant extracts such as Pronalen Bioprotect TM from Provital, antiradicals such as vitamin E, co enzyme 010, bioflavonoids, SOD, phytantriol, lignans, melatonin, pidolates, glutathione.

According to a preferred embodiment, the composition used according to the invention contains at least one UV filter (or sunscreen) which may be a chemical filter or a physical filter or a mixture of such filters. By way of illustration and in a nonlimiting manner, mention may be made of the following families (the names correspond to the CTFA nomenclature of the filters): anthranilates, in particular menthyl anthranilate; benzophenones, in particular benzophenone-1, benzophenone-3, benzophenone-5, benzophenone-6, benzophenone-8, benzophenone-9, benzophenone-12, and preferentially benzophenone-2 (oxybenzone), or Benzophenone-4 (Uvinul M540 available from BASF); benzylidenecamphers, in particular 3-benzylidene camphor, benzylidenecamphosulfonic acid, camphor benzalkonium methosulphate, polyacrylamidomethylbenzylidene camphor, terephthalylidene di-camphorsulfonic acid, and preferentially 4-methylbenzylidene camphor (Eusolex 6300 available). at Merck); benzimidazoles, in particular benzimidazilate (Neo Heliopan AP available from Haarmann and Reimer), or phenylbenzimidazole sulfonic acid (Eusolex 232 available from Merck); benzotriazoles, in particular trisiloxane drometzol, or methylene bis-benzotriazolyltetramethylbutylphenol (Tinosorb M available from Ciba); cinnamates, in particular cinoxate, DEA methoxycinnamate, diisopropyl methylcinnamate, dimethoxycinnamate glyceryl ethylhexanoate, isopropyl methoxycinnamate, isoamyl cinnamate, and preferably ethocrylene (Uvinul N35 available from BASF), octyl methoxycinnamate (Parsol MCX available from Hoffmann La Roche), or octocrylene (Uvinul 539 available from BASF); dibenzoylmethanes, in particular butyl methoxydibenzoylmethane (Parso11789); imidazolines, in particular ethylhexyl dimethoxybenzylidene dioxoimidazoline; PABAs, in particular ethyl dihydroxypropyl PABA, ethylhexyldimethyl PABA, glyceryl PABA, PABA, PEG-25 PABA, and preferentially diethylhexylbutamido-triazone (Uvasorb HEB available from 3V Sigma), ethylhexyltriazone (Uvinul 1150 available from BASF), or ethyl PABA (benzocaine); salicylates, especially dipropylene glycol salicyclate, ethylhexyl salicylate, homosalate, or TEA salicylate; triazines, in particular anisotriazine (Tinosorb S available from Ciba); trisiloxane drometrizole, zinc oxide, titanium dioxide, zinc oxide, iron, zirconium, cerium coated or uncoated. The amount of filters depends on the desired end use. It may range, for example, from 1 to 20% by weight and better still from 2 to 10% by weight relative to the total weight of the composition.

The cosmetic compositions may be applied directly to the skin or, alternatively, to occlusive or non-occlusive cosmetic or dermatological carriers intended to be applied in a localized manner to the skin. The support can be an "occlusive" support. By way of example, the support consists of a thermoplastic material chosen from high and low density polyethylenes, polypropylenes, polyvinyl chlorides, copolymers of ethylene and vinyl acetate, polyesters and polyurethanes. , or a complex of such materials. These materials may also be present in laminated form with at least one sheet of metal such as aluminum foil.

The support layer may be of any suitable thickness which will provide the desired support and protection functions. Preferably, the thickness of the support layer is from about 20 μm to about 1.5 mm. Advantageously, the support layer is sufficiently flexible so as to perfectly fit the profile of the skin, and not to cause the user, a feeling of discomfort.

Preferably, however, the carrier is "non-occlusive". In the latter case, it is advantageous to use a support consisting of a paper, a porous or perforated thermoplastic material, a woven fabric, a nonwoven fabric or a perforated nonwoven fabric. According to another embodiment, said compositions for use according to the invention can be combined with compositions administered orally, containing additional cosmetic active agents with a beneficial effect on the appearance of the skin, such as, for example, active ingredients. additives to combat the signs of skin aging or additional active ingredients to fight against oily skin. Additional active ingredients The composition according to the invention may further contain other active agents, and in particular at least one compound chosen from: moisturizing agents; depigmenting agents; anti-aging / anti-wrinkle agents (anti-glycation agents; NO-synthase inhibitors; agents stimulating the synthesis of dermal or epidermal macromolecules and / or preventing their degradation; agents stimulating the proliferation of fibroblasts and / or keratinocytes or stimulating differentiation of keratinocytes; muscle relaxants); agents having a restructuring effect of the cutaneous barrier function; agents promoting the maturation of the horny envelope; agents promoting cutaneous microcirculation; agents stimulating cellular energy metabolism of cells; tensors; antioxidants; anti-pollution and / or anti-radical agents, desquamating agents, sunscreens, and mixtures thereof. "Moisturizing agent" means: either a compound acting on the barrier function, with a view to maintaining the hydration of the stratum corneum, or an occlusive compound. There may be mentioned ceramides, sphingaide-based compounds, lecithins, glycosphingolipids, phospholipids, cholesterol and its derivatives, phytosterols (stigmasterol, [3-sitosterol, campesterol), essential fatty acids, 1-2 diacylglycerol 4-chromanone, pentacyclic triterpenes such as ursolic acid, petrolatum and lanolin; or a compound directly increasing the water content of the stratum corneum, such as thralose and its derivatives, hyaluronic acid and its derivatives, glycerol, pentanediol, sodium pidolate, serine, xylitol, lactate sodium, glycerol polyacrylate, ectaine and its derivatives, chitosan, oligo- and polysaccharides, cyclic carbonates, N-lauroyl pyrrolidone carboxylic acid, and Na-benzoyl-L-arginin; or a compound that activates the sebaceous glands, such as DHEA, its oxidized and / or 17-alkylated derivatives, sapogenins and vitamin D and its derivatives. The "depigmenting agents" that may be incorporated into the composition according to the present invention comprise, for example, the following compounds: kojic acid; ellagic acid; arbutin and its derivatives such as those described in EP-895,779 and EP-524,109; hydroquinone; aminophenol derivatives such as those described in applications WO 99/10318 and WO 99/32077, and in particular N-cholesteryloxycarbonyl-para-aminophenol and N-ethyloxycarbonyl-para-aminophenol; iminophenol derivatives, in particular those described in application WO 99/22707; L-2-oxothiazolidine-4-carboxylic acid or procysteine, as well as its salts and esters; ascorbic acid and its derivatives, especially ascorbyl glucoside; and plant extracts, in particular licorice, mulberry and skullcap, without this list being limiting. By "anti-glycation agent" is meant a compound that prevents and / or decreases the glycation of skin proteins, in particular dermal proteins such as collagen.

Examples of anti-glycation agents are plant extracts of the family Ericaceae, such as a bilberry extract (Vaccinium angustifolium); ergothioneine and its derivatives; and hydroxystilbenes and their derivatives, such as resveratrol and 3,3 ', 5,5'-tetrahydroxystilbene. Examples of "NO synthase inhibitors" that are suitable for use in the present invention include, in particular, a plant extract of the Vitis vinifera species which is marketed in particular by Euromed under the name Leucocyanidines of extra grapes, or by lndena under the name Leucoselect®, or finally by Hansen under the name Grape Marsh Extract; a plant extract of the species Olea europaea which is preferably obtained from olive leaves and is especially marketed by VINYALS in the form of dry extract, or by Biologia & Technologia under the trade name Eurol BT ; and an extract of a plant of the Gingko biloba species which is preferably a dry aqueous extract of this plant sold by Beaufour under the trade name Ginkgo biloba standard extract. Among the "agents stimulating the macromolecules of the dermis or preventing their degradation", mention may be made of those which act: either on the synthesis of collagen, such as extracts of Centella asiatica; asiaticosides and derivatives; ascorbic acid or vitamin C and its derivatives; synthetic peptides such as iamin, the biopeptide CL or palmitoyloligopeptide marketed by SEDERMA; peptides extracted from plants, such as the soy hydrolyzate marketed by the company Coletica under the trade name Phytokine®; and plant hormones such as auxins and lignans. or on the synthesis of elastin, such as the extract of Saccharomyces Cerivisiae sold by the company LSN under the trade name Cytovitin®; and the algae extract Macrocystis pyrifera marketed by SECMA under the trade name Kelpadelie®; or on the synthesis of glycosaminoglycans, such as the product of fermentation of milk with Lactobacillus vulgaris, sold by BROOKS under the trade name Biomin yogourth®; the extract of the brown alga Padina pavonica marketed by ALBAN MÜLLER under the trade name HSP3®; and the Saccharomyces cerevisiae extract available in particular from the company Silab under the trade name Firmalift® or from the company LSN under the trade name Cytovitin®; or on the synthesis of fibronectin, such as the Saline zooplankton extract marketed by Seporga under the trade name GP4G®; yeast extract available in particular from ALBAN MÜLLER under the trademark Drieline®; and the palmitoyl pentapeptide marketed by SEDERMA under the trade name Matrixil®; or on the inhibition of metalloproteinases (MMPs) such as, more particularly, MMPs 1, 2, 3, 9. Mention may be made of: retinoids and derivatives, oligopeptides and lipopeptides, lipoamino acids, malt extract marketed by the company COLETICA under the trade name Collalift®; extracts of blueberry or rosemary; lycopene; isoflavones, their derivatives or plant extracts containing them, in particular extracts of soya (marketed for example by the company Ichimaru PHARCOS under the trade name Flavosterone SBO), red clover, flax, kakkon or sage; or on the inhibition of serine proteases such as leukocyte elastase or cathepsin G. Mention may be made of: the peptide extract of leguminous seeds (Pisum sativum) sold by the company LSN under the trade name Parelastyl®; heparinoids; and pseudodipeptides such as {2- [acetyl- (3-trifluoromethyl-phenyl) -amino] -3-methyl-butyrylamino} -acetic acid.

Among the "active agents stimulating epidermal macromolecules", such as fillagrine and keratins, there may be mentioned in particular the lupine extract marketed by SILAB under the trade name Structurine®; the extract of Fagus sylvatica beech buds marketed by Gattefosse under the trade name Gatuline®; and Salina zooplankton extract marketed by SEPORGA under the trade name GP4G®. The "fibroblast proliferation stimulating agents" that can be used in the composition according to the invention may, for example, be chosen from plant proteins or polypeptides, extracted especially from soybeans (for example a soybean extract marketed by LSN under the name Eleseryl SH). -VEG 8® or sold by the company SILAB under the trade name Raffermine®); and plant hormones such as giberrellins and cytokinins. "Agents stimulating the proliferation of keratinocytes", usable in the composition according to the invention, include retinoids such as retinol and its esters, including retinyl palmitate; phloroglucinol; nut cake extracts sold by the company GATTEFOSSE; and extracts of Solanum tuberosum marketed by SEDERMA. "Agents stimulating the differentiation of keratinocytes" include, for example, minerals such as calcium; the lupine extract marketed by SILAB under the trademark Photopréventine®; sodium beta-sitosteryl sulphate marketed by Seporga under the trade name Phytocohesine®; and the corn extract marketed by SOLABIA under the trademark Phytovityle; and lignans such as secoisolariciresinol. The composition according to the invention may comprise "dermodecontracting agents", among which mention may in particular be made of alverine and its salts, in particular alverine citrate, sapogenins such as diosgenin and the natural extracts containing them (such as extracts of Wild Yam), certain secondary and tertiary carbonyl amines, organic or inorganic metal salts, in particular manganese gluconate, adenosine, and the hexapeptide argireline R marketed by LIPOTEC. There may also be mentioned certain perfume compositions with a dermo-decontracting effect.

As "agent having a restructuring effect of the skin barrier", there may be mentioned an extract of Thermus thermophilus such as Sederma Venuiteane®, an extract of wild yam rhizome (Dioscorea villosa) such as Actigen Y®. Active Organics, plankton extracts such as Secma's omega plancton®, yeast extracts such as Coletica's Relipidium®, a chestnut extract such as Silab's Recoverine®, a cedar bud extract such as Gatuline Zen Gattefossé ®, Degussa Phytosphingosine SLC, Seppic Aquaxyl ®, Coletica Lipidessence ®. There may also be mentioned ceramides and derivatives, compounds based on sphingoids, glycosphingolipids, phospholipids, cholesterol and its derivatives, phytosterols, essential fatty acids, diacylglycerol, 4-chromanone and chromon derivatives, the vaseline, lanolin, shea butters, cocoa butter, lanolin, etc. As preferred additional agents promoting the cutaneous barrier function, an extract of Thermus thermophilus, an extract of wild yam rhizome (dioscorea villosa), will be mentioned. yeast extract, chestnut extract, cedar bud extract and mixtures thereof.

As "agents promoting the maturation of the horny envelope", it will be possible to use, in the compositions of the invention, agents which mediate the maturation of the horny envelope, which deteriorates with age and induces a decrease in of transglutaminase activity. There may be mentioned, for example, urea and its derivatives and, in particular, Hydrovance® from National Starch and the other active agents mentioned in L'OREAL application FR2877220. As "agents promoting cutaneous microcirculation", it is possible to combine in the compositions of the invention agents acting on the cutaneous microcirculation in order to avoid dulling of the complexion and / or the formation of the pockets, for example an extract of black tea such as Sederma Kombuchka, Pycnogenol, Manganese Gluconate (Givobio GMn Seppic), Indena Visnadine, Lupine Extract (Eclaline Silab), Epaline 100 Carilene Laboratories, an extract from bigarade flower (ilab remodulin), vitamin P and its derivatives such as Permethol Sochibios and other extracts (ruscus, chestnut, ivy, ginseng, sweetclover ...) and also caffeine, escin , hesperitin laurate, dextran sulfate, nicotinate and derivatives, lysine and derivatives (such as Asparlyne of Solabia) ...

Preferred additional agents promoting cutaneous microcirculation include Kombuchka, manganese gluconate and vitamin P and its derivatives. By "agents stimulating the energetic metabolism of the cells", it is also possible to associate active agents stimulating the energetic metabolism which is slowed down during aging, among which mention may be made of biotin, an extract of Saccharomyces cerevisaie such as Phosphovital® from Sederma, Physiogenyl® from Solabia, a mixture of zinc gluconate, copper and magnesium such as Sepitonic M3® from Seppic. By "tensing agent" is meant a compound capable of exerting traction on the skin.

As "antioxidant" agents, there may be mentioned in particular tocopherol and its esters, in particular tocopherol acetate; BHT, Tinoguard TT and BHA. There may also be mentioned polyphenols, tannic acid, epoigallocathechins and natural extracts containing them, anthocyanins, rosemary extracts, olive leaf extracts, green tea, resveratrol and its derivatives, Pycnogenol , ergothineine, N acetylcysteine, biotin, chelants, idebenone, plant extracts such as Pronalen Bioprotect TM from Provital, antiradicals such as vitamin E, co enzyme 010, bioflavonoids, SOD, phytantriol, lignans, melatonin, pidolates, glutathione. By the term "anti-pollution agent" is meant any compound capable of trapping ozone, mono- or polycyclic aromatic compounds such as benzopyrene and / or heavy metals such as cobalt, mercury, cadmium and / or nickel. By "anti-radical agent" is meant any compound capable of trapping free radicals. As "ozone trapping agents" that may be used in the composition according to the invention, mention may be made in particular of vitamin C and its derivatives including ascorbyl glucoside; phenols and polyphenols, in particular tannins, ellagic acid and tannic acid; epigallocatechin and natural extracts containing it; olive leaf extracts; tea extracts, especially green tea; anthocyanins; rosemary extracts; phenolic acids, in particular chorogenic acid; stilbenes, in particular resveratrol; sulfur-containing amino acid derivatives, in particular S-carboxymethylcysteine; ergothioneine; N-acetylcysteine; chelating agents such as N, N'-bis- (3,4,5-trimethoxybenzyl) ethylenediamine or a salt thereof, metal complexes or esters; carotenoids such as crocetin; and various raw materials such as the mixture of arginine, histidine ribonucleate, mannitol, adenosinetriphosphate, pyridoxine, phenylalanine, tyrosine and hydrolysed RNA marketed by Serobiological Laboratories under the trade name CPP LS 2633-12F®, the water soluble fraction of corn marketed by the company SOLABIA under the trade name Phytovityl®, the mixture of fumitory extract and lemon extract marketed under the name Unicotrozon C-49® by the company Induchem, and the mixture of extracts of ginseng, apple , peach, wheat and barley sold by the company PROVITAL under the trade name Pronalen Bioprotect®. As "scavengers of mono- or polycyclic aromatic compounds" usable in the composition according to the invention, mention may in particular be made of tannins such as ellagic acid; indole derivatives, in particular indol-3-carbinol; tea extracts especially green tea, extracts of water hyacinth or eichornia crassipes; and the water-soluble corn fraction marketed by SOLABIA under the trade name Phytovityl®. Finally, as "heavy metal scavengers" usable in the composition according to the invention, mention may in particular be made of chelating agents such as EDTA, pentasodium salt of ethylenediamine tetramethylene phosphonic acid, and N, N'-bis. - (3,4,5-trimethoxybenzyl) ethylenediamine or a salt thereof, metal complexes or esters; phytic acid; chitosan derivatives; tea extracts, especially green tea; tannins such as ellagic acid; sulfur-containing amino acids such as cysteine; water hyacinth (Eichornia crassipes) extracts; and the water-soluble corn fraction marketed by SOLABIA under the trade name Phytovityl®. The "anti-radical agents" that can be used in the composition according to the invention comprise, in addition to certain anti-pollution agents mentioned above, vitamin E and its derivatives such as tocopheryl acetate; bioflavonoids; coenzyme 010 or ubiquinone; certain enzymes such as catalase, superoxide dismutase, lactoperoxidase, glutathione peroxidase and quinone reductases; glutathione; benzylidene camphor; benzylcyclanones; substituted naphthalenones; pidolates; phytantriol; gamma-oryzanol; lignans; and melatonin. By "desquamating agent" is meant any compound capable of acting: either directly on the desquamation by promoting exfoliation, such as p-hydroxy acids, in particular salicylic acid and its derivatives (the acid of which 5-salicylic octanoyl); α-hydroxy acids, such as glycolic, citric, lactic, tartaric, malic or mandelic acids; urea; gentisic acid; oligofucoses; cinnamic acid; Saphora japonica extract; resveratrol; or on the enzymes involved in the desquamation or degradation of corneodesmosomes, such as glycosidases, stratum corneum chymotryptic enzyme (SCCE) or even other proteases (trypsin, chymotrypsin-like). Mention may be made of the chelating agents for mineral salts: EDTA; N-acyl-N, N ', N', ethylene diaminetriacetic acid; aminosulfonic compounds and in particular N- (2-hydroxyethyl) piperazine-N'-2-ethanesulfonic acid (HEPES); 2-oxothiazolidine-4-carboxylic acid derivatives (procysteine); glycine-type alpha amino acid derivatives (as described in EP-0 852 949, as well as the sodium methyl glycine diacetate marketed by BASF under the trade name TRILON M); honey ; sugar derivatives such as O-octanoyl-6-D-maltose and N-acetyl glucosamine. These cosmetic compositions may, for example, constitute creams for cleaning, protecting, treating or caring for the face, the neck, the hands, the feet, the large anatomical folds or the body (for example creams of day, night creams, make-up removal creams, foundation creams, sunscreen creams), fluid foundations, make-up removing milks, body care or protection milks, sunscreen milks, lotions skin care gels or mousses, such as cleaning lotions, sunscreen lotions, artificial tanning lotions, bath compositions, deodorant compositions comprising a bactericidal agent, aftershave gels or lotions , depilatory creams. The compositions according to the invention may also consist of solid preparations constituting soaps or cleaning bars. The compositions may also be packaged in the form of an aerosol composition also comprising a propellant under pressure.

By way of example, a composition for implementing the method according to the invention is a direct oil / water emulsion for the daily care of the face and / or the neck of the following composition (expressed in percentage by weight): Ingredients INCI name or chemical name (3/0 by weight DISODIUM EDTA 0.05 SODIUM CITRATE 0.1 GLYCERIN (and) TREHALOSE (and) TAMARINDUS INDICA SEED POLYSACCHARIDE (and) MYROTHAMNUS FLABELLIFOLIA LEAF EXTRACT (PA REVIVISCENCE LS 9562 from BASF) 1 RHAMNOSE ( L-RHAMNOSE ™ from DANISCO) 5 PHENOXYETHANOL 0.4 ZEA MAYS (CORN) GERM OIL 3 BEESWAX 1 BUTYROSPERMUM PARKII (SHEA) BUTTER 4 CETYL ALCOHOL 1.5 MYRISTYL MYRISTATE 1 Vegetable oil 3 SODIUM HYALURONATE 0.15 ACRYLAMIDE / SODIUM ACRYLOYLDIMETHYLTAURATE COPOLYMER (and) ISOHEXADECANE (and) POLYSORBATE 80 1,3 ACRYLATES / C10-30 ALKYL ACRYLATE CROSSPOLYMER 0.1 DIMETHICONE 4 POLYSILICONE-11 7 WATER QSP 100 GLYCERIN 7 PENTYLENE GLYCOL 5 CAPRYLYL GLYCOL 0.35 STEARIC ACID 1.5 GLYCERYL STEARATE (and) PEG-100 STEARATE 4 SORBITAN TRISTEARATE 0.9 GLYCERYL STEARATE 0.5 DESCRIPTION OF THE FIGURES FIG. 1: Illustration of the evolution of the consumption of glucose (1A) or the synthesis of ATP (1B) in keratinocytes as a function of the presence of extract of Myrothamnus flabellifolia at 11 × 10 -4% or at 22 × 10 -5% in DM of extract in the culture medium. FIG. 2: Graphical representation of the synthesis of zonulin-1 protein (ZO-1) in keratinocytes as a function of the presence of Myrothamnus flabellifolia extract (11 × 10 -4% or at 22 × 10 -5% in extract MS) and / or L-Rhamnose (0.16 mg / ml or 0.8 mg / ml) in the culture medium.

FIG. 3: Graphical representation of the synthesis of the integrin alpha 4 protein in keratinocytes as a function of the presence of Myrothamnus flabellifolia extract (11 × 10 -4% or at 22 × 10 -5% in extract MS) and / or L -Rhamnose (0.16 mg / ml or 0.8 mg / ml) in the culture medium. FIG. 4: Illustration of the evolution of ATP synthesis in keratinocytes as a function of the presence of Myrothamnus flabellifolia extract (11 × 10 -4% in MS of Myrothamnus Flabellifolia extract) and / or L-Rhamnose ( 0.8 mg / ml) in the culture medium. Figure 5: Illustration of the evolution of the NAD / NADH ratio in keratinocytes as a function of the presence of Myrothamnus flabellifolia extract (11.10-4% in MS of Myrothamnus Flabellifolia extract) and / or L-Rhamnose (0 , 8 mg / ml) in the culture medium.

The following examples illustrate the invention without limiting its scope. EXAMPLES Example 1 Stimulation of keratinocyte metabolism by an extract of Myrothamnus Flabellifolia Protocol: Myrothamnus Flabellifolia extract solution A stock solution containing 1% active ingredient (extract MS) is obtained according to the process described in application US2007. / 0134193.

This stock solution is then diluted to 0.11% and 0.022% by volume for the following tests so as to contain 22.10-5% or 11.10-4% by weight of MS of Myrothamnus Flabellifolia extract. Cell Culture The keratinocytes were cultured in culture medium (Keratinocyte SFM supplemented with 0.25 ng / ml Epidermal growth factor, 2514 / ml pituitary extract and 254 / ml gentamycin) for 24 hours. After incubation, the culture medium was replaced with a culture medium not supplemented or supplemented with EGF and pituitary extract containing or not (control) 22.10-5% or 11.104% (by weight of MS) of Myrothamnus Flabellifolia extract. . The measurement of ATP content (measured using a specific kit according to the supplier's recommendations: ATP Biolum, Roche) was carried out at 2 hours. The tests are carried out in triplicas and the averages of the measurements are presented in Table 1. The glucose measurement was quantified by the colorimetric method with O-toluidine. Treatment 2h Basic data Compounds Concentration Average of 3 esm% esm (1) tested replicas (pm) Control (0/0) P ATP (-1M) Control 0.116 0.002 100 2 SVF 10% 0.147 0.03 127 26 ns Extract 0.00022% 0.147 0.013 127 11 ns Myrothamnus flabellifolia 0.0011% 0.160 0.012 138 11 (1) = Threshold of statistical significance ns:> 0.05, Not significant *: 0.01 to 0.05, Significant **: 0.001 to 0.01, Very significant ***: <0.001, Extremely significant Table 1: Effect of Rhamnose, Myrothamnus flabellifolia extract and their association on the intracellular concentration of ATP in keratinocytes cultured in culture medium 2h. Analysis of the results Increase of the glucose consumption by the keratinocytes: In a non-deficient medium containing an extract of Myrothamnus Flabellifolia, from 22.10-5% in MS, a stimulation of glucose consumption after 24 hours of treatment in culture medium was observed (+ 186% relative to the control) (FIG. 1A). This effect was not observed in a deficient environment.

Increase in dATP synthesis in keratinocytes: In a non-deficient medium containing an extract of Myrothamnus Flabellifolia, a slight increase in ATP synthesis was observed 2 hours after treatment, in the presence of Myrothamnus Flabellifolia extract at 22.10-5. % or 11.10-4% (in MS) of extract (+27 and + 38% respectively relative to the control) (Table 1 and Figure 1B). This effect was not observed when the cells were incubated in a deficient medium. EXAMPLE 2 Stimulation of the Establishment of Tight Junctions by an Extract of Myrothamnus Flabellifolia in Association or Not with L-Rhamnose Protocol The extract solutions of Myrothamnus Flabellifolia are obtained as above. L-rhamnose (L-RHAMNOSE TM from DANISCO) is used to obtain culture media at 0.8 mg / ml and 0.16 mg / ml L-rhamnose. The keratinocytes were cultured for 24 hours. After incubation, the culture medium was replaced with a test medium containing or not the test compounds (Myrothamnus flabellifolia extract 11.10-4`) / 0 or 22.10-5 ° / o in MS extract and / or or 0.16 mg / ml or 0.8 mg / ml rhamnose), and then the cells were incubated for 72 hours. After washing, the cells were fixed and permeabilized. The cells were labeled with a primary antibody anti-ZO itself revealed by a secondary antibody coupled to a fluorochrome. Image acquisition was performed using an INCELL AnalyzerTM1000 (GE Healthcare). The markings were quantified by measuring the fluorescence intensity relative to the number of nuclei identified after Hoescht labeling. The tests are carried out in triplicas and the averages of the measurements are presented in Table 2.

Analysis of the results The myrothamnus extract tested at 0.11% (11.10-4% in MS of Myrothamnus Flabellifolia extract) alone and in combination with rhamnose (0.8 mg / ml) induced a statistically significant increase in the synthesis of ZO-1 protein (Table 2 and Figure 2). It should be noted that there is no significant stimulation of ZO-1 synthesis by rhamnose alone at 0.8 mg / ml or 0.16 mg / ml. This observation reflects a potentiating effect of rhamnose vis-à-vis the effect of the extract of Myrothamnus Flabellifolia on the increase of ZO-1 synthesis.

Compounds Concentration tested esm cyo esm ZO-1 Control (0/0) Average of three replicas of Fluorescence Surfaces / Number of cells (UA) Control 14 1,100 4 - CaC12 1.5 mM 16 0 120 4 TGF-B 10 ng / ml 13 0 96 1 ns Rhamnose 0.16 mg / mi 16 1 116 5 ns 0.8 mg / mi 15 1 110 7 ns Extract 0.00022% 15 1 113 6 ns Myrothamnus flabellifolia 0.0011% 18 1 133 10 Mixture Rhamnose - 16 1 116 6 ns Rhamnose 0.16 mg / mi + Extract - 0.00022% extract Myrothamnus flabellifolia Rhamnose - 18 1 135 8 0.8 mg / mi Extract - 0.0011% (1) = Threshold of statistical significance ns:> 0.05, Not significant; *: 0.01 to 0.05 Significant; **: 0.001 to 0.01, Very significant ***: <0.001, Extremely significant Table 2: Effect of Rhamnose, Myrothamnus flabellifolia extract and their association on ZO-1 protein expression at the level of of the plasma membrane in keratinocyte cultures. Relative quantification by image analysis after immunostaining in situ. EXAMPLE 3 Stimulation of the Establishment of Hemidesmosomes of JDE by an Extract of Myrothamnus Flabellifolia in Association or Not with Rhamnose Protocol The solutions of extract of Myrothamnus Flabellifolia are obtained as above. L-rhamnose (L-RHAMNOSE TM from DANISCO) is used to obtain culture media at 0.8 mg / ml and 0.16 mg / ml L-rhamnose.

The keratinocytes were cultured for 24 hours. After incubation, the culture medium was replaced with a test medium containing or not containing Myrothamnus flabellifolia extract (11.10-4% or 22.10-5% in extract MS) and / or rhamnose (0 16mg / ml or 0.8mg / ml), then the cells were incubated for 72 hours. After washing, the cells were fixed and permeabilized. The cells were labeled with a primary antibody anti-integrin alpha 4 itself revealed by a secondary antibody coupled to a fluorochrome. Image acquisition was performed using an INCELL AnalyzerTM1000 (GE Healthcare). The labels were quantified by measuring the fluorescence intensity relative to the number of nuclei identified after Hoescht labeling. The tests are made in triplicas and the averages are presented in Table 3.

Analysis of the results The extract of Myrothamnus Flabellifolia alone (at 11.10-4% or at 22.10-5% in MS of Myrothamnus Flabellifolia extract) induces a significant increase in the synthesis of the integrin alpha 4 (at least + 47% relative to the untreated control) (Table 3 and Figure 3). Under these same experimental conditions the presence of rhamnose at 0.8 mg / ml or at 0.16 mg / ml is devoid of effect. However, the combination of these two compounds leads to an increase of at least + 131% compared to the untreated control. These results demonstrate the potentiating effect of rhamnose on the effect of the extract of Myrothamnus Flabellifolia on the expression of the integrin alpha 4. Compounds Concentration Integral alpha 4 esm esm P tested Average (3 replicas) Control (0/0) Fluorescence Surfaces / Number of Cells (AU) Control 3027 258 100 9 - CaC12 1.5 mM 2503 765 83 25 ns TGF-B 10 ng / ml 8663 1302 286 43 Rhamnose 0.16 mg / mi 3593 334 119 11 ns 0.8 mg / mi 4517 709 149 23 ns Extract of 0.00022% 5437 500 180 17 Myrothamnus flabellifolia 0.0011% 4448 420 147 14 Rhamnose Mix - 4921 735 163 24 ns Rhamnose 0.16 mg / mi + Extract - Extract of 0.00022% Myrothamnus flabellifolia Rhamnose - 6999 699 231 23 ** 0.8 mg / ml Extract - 0.0011% (1) = Threshold of statistical significance ns:> 0.05, Not significant *: 0.01 to 0.05, Significant **: 0.001 to 0.01, Very Significant ***: <0.001, Extremely Significant Table 3: Effect of Rhamnose, Myrothamnus flabellifolia Extract and Leu r association on the expression of integrin alpha-4 in keratinocyte cultures. Relative quantification by image analysis after immunostaining in situ.

EXAMPLE 4 Synergistic Effect Between an Extract of Myrothamnus Flabellifolia and Rhamnose in the Stimulation of Keratinocyte Metabolism Protocol The keratinocytes were cultured in culture medium (Keratinocyte SFM) supplemented with Epidermal growth factor 0.25 ng / ml, Pituitary extract 25 pg / m1 and gentamicin 25pg / ml, for 24 hours. After incubation, the culture medium was replaced by a culture medium not complemented or supplemented with EGF and pituitary extract containing or not (control) extract of Myrothamnus flabellifolia (11.104% in MS of extract of Myrothamnus Flabellifolia) and / or rhamnose (0.8 mg / ml). Measurement of ATP content (measured using a specific kit according to ATP Biolum Roche's recommendations) was carried out at 2 hours. The tests are carried out in triplicas and the averages of the measurements are presented in Table 1. The NAD / NADH ratio was measured using a specific kit according to the recommendations of the supplier BioVision). The tests are carried out in triplicas and the averages of the measurements are presented in Table 4. Analysis of the results Increase of dATP synthesis in keratinocytes. The extract of myrothamnus, tested at 0.0011% in MS extract significantly increased the ATP content after 2 hours of treatment (+ 38%) (see Table 1 and Figure 4). Under these same conditions, rhamnose increased the intracellular content of ATP after 2 hours of treatment in culture medium compared to the untreated control (+ 44%). The combination of Myrothamnus flabellifolia extract and rhamnose led to an increase in ATP content of + 20%.

Increase of NAD / NADH synthesis in keratinocytes. In a deficient culture medium, Myrothamnus flabellifolia tested at 0.00022% DM (not shown) or 0.0011% (Table 4 and Figure 5) does not affect the NAD / NADH ratio relative to the control. Under these same conditions, the rhamnose at 0.8 mg / mi or 0.16 mg / mi does not lead, too, to a modulation of this ratio. However, the combination of these two compounds leads to a significant increase in the NAD / NADH ratio (+20 and + 22% compared with the control at 24h) .35 24h treatment Compounds Mean concentration of esm (3/0 esm P (1) ) tested three replicates (0/0) Ratio NAD / NADH Control 2.1 0.1 100 4 SVF 10% 2.3 0.2 107 9 ns Rhamnose 0.16 mg / mi 2.4 0.0 112 2 ns 0.8 mg / mi 2.3 0.1 107 4 ns Extract of 0.00022% 1.9 0.5 89 24 ns Myrothamnus flabellifolia 0.0011% 1.2 0.5 69 23 ns Mixture Rhamnose - 2.5 0.1 120 6 Rhamnose 0.16 mg / ml + Extract of Myrothamnus Extract Myrothamnus flabellifolia- flabellifolia 0.00022% Rhamnose - 2.6 0.0 122 2 ** 0.8 mg / mi Myrothamnus flabellifolia extract - 0.0011% (1) = Threshold of statistical significance ns:> 0.05 Not significant *: 0.01 to 0.05 Significant ** : 0.001 to 0.01 Very significant * ": <0.001 Extremely significant Table 4: Effect of Rhamnose, Myrothamnus flabellifolia Extract and their association on the NAD / NADH ratio in keratinocytes cultured in a deficient medium for 24 hours10

Claims (16)

CLAIMS 1. A cosmetic treatment method for decreasing and / or delaying thinning of the skin and / or relaxation of the skin and / or improving the mechanical strength of the skin and / or the density of the skin, characterized in that apply an effective amount of Myrothamnus flabellifolia extract to the skin. 2. A process according to claim 1, characterized in that it is intended to stimulate the cellular metabolism of keratinocytes and / or the migration and / or proliferation of keratinocytes and / or to reinforce the cohesion between the epidermal cells and / or between epidermal cells and the extracellular matrix. 3. A process according to either of claims 1 and 2, characterized in that it is intended to stimulate the formation of desmosomes, hemidesmosomes, focal-contacts and / or tight junctions of the epidermis . 4. A process according to any one of claims 1 to 3, characterized in that it is intended to strengthen the dermal-epidermal junction. 5. A process according to any one of claims 1 to 4, characterized in that it is intended to stimulate the synthesis of integrin and / or zonulin by keratinocytes. 6. A process according to any one of claims 1 to 5, characterized in that the extract of Myrothamnus flabellifolia is formulated in a cosmetic composition further comprising rhamnose. 7. A process according to claim 6, characterized in that the extract of Myrothamnus flabellifolia is present in the composition at a content of 10-6 to 10% by weight of extract, relative to the total weight of the composition. 8. A process according to either of claims 6 and 7, characterized in that the rhamnose is present in the composition in a content of 0.001 to 30% by weight of rhamnose, relative to the total weight of the composition .35 9. A process according to any one of claims 6 to 8, characterized in that the weight ratio between the rhamnose and the extract of Myrothamnus flabellifolia in the composition is greater than 1. 10. Composition comprising an extract of Myrothamnus flabellifolia, rhamnose and a cosmetically acceptable medium. 11. Composition according to claim 10, characterized in that the rhamnose is added to the extract of Myrothamnus flabellifolia in said composition. 12. Composition according to either of Claims 10 and 11, characterized in that it comprises, by weight relative to the total weight of the composition, from 0.001 to 30% of rhamnose, and / or from 10 to 6% by weight. % of Myrothamnus flabellifolia extract. 13.- Cosmetic treatment process for decreasing and / or delaying the thinning of the skin and / or the relaxation of the skin and / or improving the mechanical strength of the skin and / or the density of the skin and / or the skin barrier function, characterized in that an effective amount of the composition according to any one of claims 10 to 12 is applied to the skin. 14.- Use of an extract of Myrothamnus flabellifolia as an agent for decreasing and / or delaying thinning of the skin and / or loosening of the skin and / or improving the mechanical strength of the skin and / or the density of the skin the skin, said extract of Myrothamnus flabellifolia being contained in a cosmetic composition. 15. Use according to claim 14, said composition further comprising at least rhamnose. 16. Process for preparing a cosmetic composition according to any one of claims 10 to 12 comprising at least one step of mixing rhamnose, an extract of Myrothamnus flabellifolia and a cosmetically acceptable medium.